SG11202009649RA - Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer - Google Patents

Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer

Info

Publication number
SG11202009649RA
SG11202009649RA SG11202009649RA SG11202009649RA SG11202009649RA SG 11202009649R A SG11202009649R A SG 11202009649RA SG 11202009649R A SG11202009649R A SG 11202009649RA SG 11202009649R A SG11202009649R A SG 11202009649RA SG 11202009649R A SG11202009649R A SG 11202009649RA
Authority
SG
Singapore
Prior art keywords
psma
diagnosing
prostate cancer
treating prostate
targeted radiopharmaceutical
Prior art date
Application number
SG11202009649RA
Inventor
Dae Yoon Chi
Byoung Se Lee
So Young Chu
Hyeon Jin Jeong
Min Hwan Kim
Original Assignee
Futurechem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futurechem Co Ltd filed Critical Futurechem Co Ltd
Publication of SG11202009649RA publication Critical patent/SG11202009649RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0487Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202009649RA 2018-03-30 2019-03-29 Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer SG11202009649RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180037226 2018-03-30
PCT/KR2019/003716 WO2019190266A1 (en) 2018-03-30 2019-03-29 Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer

Publications (1)

Publication Number Publication Date
SG11202009649RA true SG11202009649RA (en) 2020-10-29

Family

ID=68058285

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009649RA SG11202009649RA (en) 2018-03-30 2019-03-29 Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer

Country Status (26)

Country Link
US (1) US11931431B2 (en)
EP (1) EP3778592B1 (en)
JP (1) JP7094591B2 (en)
KR (1) KR102156385B1 (en)
CN (1) CN112004812B (en)
AU (1) AU2019243408B2 (en)
BR (1) BR112020019566A2 (en)
CA (1) CA3094620C (en)
CL (1) CL2020002510A1 (en)
DK (1) DK3778592T3 (en)
EA (1) EA202092333A1 (en)
ES (1) ES2947748T3 (en)
FI (1) FI3778592T3 (en)
HR (1) HRP20230604T1 (en)
HU (1) HUE062904T2 (en)
LT (1) LT3778592T (en)
MX (1) MX2020010266A (en)
MY (1) MY197419A (en)
PH (1) PH12020551471A1 (en)
PL (1) PL3778592T3 (en)
PT (1) PT3778592T (en)
RS (1) RS64296B1 (en)
SG (1) SG11202009649RA (en)
SI (1) SI3778592T1 (en)
WO (1) WO2019190266A1 (en)
ZA (1) ZA202006008B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102269315B1 (en) * 2019-10-24 2021-06-24 서울대학교산학협력단 A radiolabeled compound for imaging or therapy of prostate cancer
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
KR20220006286A (en) 2020-07-08 2022-01-17 한국원자력의학원 Prostate-specific Membrane Antigen Targeted Compound And Composition Comprising The Same For Diagnosis And Treatment Of Prostate Cancer
KR20230050552A (en) * 2021-10-07 2023-04-17 (주)퓨쳐켐 Gadolinium compound, and pharmaceutical composition for diagnosing and treating prostate cancer comprising the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5843338B2 (en) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Radiolabeled prostate-specific membrane antigen inhibitor
MX2015006109A (en) * 2012-11-15 2016-02-05 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells.
CN105025933B (en) 2013-01-14 2019-03-26 分子制药洞察公司 Triazine radiomimetic drug and radio-contrast agent
RS65324B1 (en) 2013-10-18 2024-04-30 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10683272B2 (en) * 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
AU2017238181B2 (en) * 2016-03-22 2021-05-27 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same

Also Published As

Publication number Publication date
HUE062904T2 (en) 2023-12-28
KR20190114908A (en) 2019-10-10
DK3778592T3 (en) 2023-06-19
WO2019190266A1 (en) 2019-10-03
LT3778592T (en) 2023-06-26
CN112004812A (en) 2020-11-27
EP3778592A4 (en) 2021-02-17
FI3778592T3 (en) 2023-06-19
RS64296B1 (en) 2023-07-31
CN112004812B (en) 2023-05-26
SI3778592T1 (en) 2023-08-31
HRP20230604T1 (en) 2023-09-29
KR102156385B1 (en) 2020-09-15
ES2947748T3 (en) 2023-08-17
US20210106701A1 (en) 2021-04-15
CL2020002510A1 (en) 2021-02-19
EP3778592A1 (en) 2021-02-17
BR112020019566A2 (en) 2021-01-05
MY197419A (en) 2023-06-16
EP3778592B1 (en) 2023-04-26
CA3094620A1 (en) 2019-10-03
CA3094620C (en) 2022-11-22
PT3778592T (en) 2023-06-19
PH12020551471A1 (en) 2021-09-01
JP2021519822A (en) 2021-08-12
AU2019243408A1 (en) 2020-10-29
AU2019243408B2 (en) 2021-10-14
MX2020010266A (en) 2020-11-06
JP7094591B2 (en) 2022-07-04
US11931431B2 (en) 2024-03-19
EA202092333A1 (en) 2021-01-21
ZA202006008B (en) 2021-10-27
PL3778592T3 (en) 2023-11-27

Similar Documents

Publication Publication Date Title
IL272470A (en) Methods and materials for assessing and treating cancer
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
ZA202006008B (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
IL282663A (en) Bt1718 for use in treating cancer
IL265786A (en) Compositions and methods for enhancing cancer radiotherapy
IL273071A (en) Diagnostic and therapeutic methods for cancer
IL271326A (en) Compositions and methods for enhancing cancer radiotherapy
IL276748A (en) Methods for prostate cancer detection and treatment
PT3609497T (en) Combination therapy for prostate cancer
GB201814866D0 (en) PeptiCRAd cancer therapy
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
GB201820660D0 (en) Cancer treatments
EP3565560A4 (en) Predictive and diagnostic methods for prostate cancer
IL282478A (en) Materials and methods for treating cancer
SG11202010528XA (en) Combinations for treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
IL265675A (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
EP3468564A4 (en) Methods for diagnosing and treating metastatic cancer
SG11202109835WA (en) Methods for predicting prostate cancer and uses thereof
GB201917428D0 (en) Prostate cancer diagnostic
IL274714A (en) Methods and materials for assessing and treating cancer
EP3675893A4 (en) Methods for treating and diagnosing metastatic liver cancer
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof